Cargando…
Drug–Drug–Gene Interactions in Cardiovascular Medicine
Cardiovascular disease remains a leading cause of both morbidity and mortality worldwide. It is widely accepted that both concomitant medications (drug–drug interactions, DDIs) and genomic factors (drug–gene interactions, DGIs) can influence cardiovascular drug-related efficacy and safety outcomes....
Autores principales: | Asiimwe, Innocent G, Pirmohamed, Munir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639705/ https://www.ncbi.nlm.nih.gov/pubmed/36353710 http://dx.doi.org/10.2147/PGPM.S338601 |
Ejemplares similares
-
Cardiovascular drugs and COVID‐19 clinical outcomes: A living systematic review and meta‐analysis
por: Asiimwe, Innocent G., et al.
Publicado: (2021) -
Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials
por: Asiimwe, Innocent G., et al.
Publicado: (2022) -
Ethnic Diversity and Warfarin Pharmacogenomics
por: Asiimwe, Innocent G., et al.
Publicado: (2022) -
Drug Induced Hypersensitivity and the HLA Complex
por: Alfirevic, Ana, et al.
Publicado: (2010) -
A reference set of clinically relevant adverse drug-drug interactions
por: Kontsioti, Elpida, et al.
Publicado: (2022)